#381 ‒ Alzheimer's disease in women: how hormonal transitions impact the female brain, the role of HRT, genetics, and lifestyle on risk, and emerging diagnostics and therapies | Lisa Mosconi, Ph.D.

Jan 26, 2026 Episode Page ↗
Overview

Neuroscientist Lisa Mosconi discusses why Alzheimer's disease disproportionately affects women, viewing it as a midlife brain event linked to menopause. She explores advanced imaging, hormone therapy nuances, and practical, evidence-based strategies for women's brain health.

At a Glance
28 Insights
2h 6m Duration
19 Topics
6 Concepts

Deep Dive Analysis

Introduction to Lisa Mosconi and her research focus

Personal motivation: Family history of Alzheimer's disease

Preclinical phase of Alzheimer's disease and patient distress

Differentiating Alzheimer's from other dementias

Why Alzheimer's disproportionately affects women

Alzheimer's as a midlife disease for women

Brain imaging techniques for Alzheimer's research

Estrogen receptor imaging in the brain

Estrogen receptor density changes during menopause

Discrepancy between blood and brain estrogen levels

The CARE Initiative: Halving women's Alzheimer's risk

APOE4 genetic risk in women versus men

Menopausal Hormone Therapy (MHT) and Alzheimer's risk

Nuances of MHT timing, formulation, and uterine status

Selective Estrogen Receptor Modulators (SERMs) for brain health

Re-evaluating estrogen's link to cancer risk

Importance of better biomarkers for women's AD research

GLP-1 agonists and their potential neuroprotective effects

Lifestyle factors for long-term brain health and cognitive resilience

Dementia vs. Alzheimer's

Dementia is an umbrella term for various disorders causing cognitive decline, with Alzheimer's being the most common type, accounting for about 70% of cases. Other forms include Lewy body, frontotemporal, and vascular dementia, each with distinct pathologies and typical presentations.

Preclinical Alzheimer's Disease

This is a phase where Alzheimer's pathology (proteins, lesions) is underway in the brain, detectable by biological markers, but objective cognitive impairment is not yet present on standard tests. This phase can last decades, with patients often subjectively aware of changes.

Alzheimer's as Midlife Disease (for women)

For women, Alzheimer's disease pathology often begins in midlife with negative brain changes, rather than being solely a disease of old age. Symptoms typically manifest later in old age, but the underlying disease process starts much earlier.

Estrogen Receptor Density Compensation

The brain actively regulates estrogen receptor density. When systemic estradiol levels decline (e.g., during menopause), the brain may upregulate estrogen receptor expression to compensate and 'grab' available estrogen, an energetically expensive process that eventually may crash.

Blood-Brain Estrogen Discrepancy

Estrogen levels measured in the circulation (blood) often have little correlation with estrogen levels or activity in the brain. Brain hormone dynamics are tightly regulated by transporters and the blood-brain barrier, sheltering the brain from rapid peripheral fluctuations.

Selective Estrogen Receptor Modulators (SERMs)

These are compounds designed to selectively bind to specific types of estrogen receptors (e.g., alpha or beta) in different parts of the body. This allows for targeted effects, such as stimulating cognitive function in the brain via beta receptors, while potentially avoiding effects on reproductive organs.

?
What is the difference between dementia and Alzheimer's disease?

Dementia is an umbrella term for various disorders causing cognitive decline, with Alzheimer's being the most common type, accounting for about 70% of cases. Other forms include Lewy body, frontotemporal, and vascular dementia, each with distinct pathologies.

?
Why are women disproportionately affected by Alzheimer's disease?

While women live longer on average, this longevity alone doesn't fully explain their nearly twofold risk. Research suggests women start developing Alzheimer's pathology earlier in midlife and may have a higher cognitive reserve, masking symptoms longer.

?
Does menopause play a significant role in women's Alzheimer's risk?

Yes, menopause is considered a fundamental brain event that reshapes brain energy use, structure, and immune signaling. The decline in estrogen levels during this transition is hypothesized to drive increased cellular aging and Alzheimer's biomarker risk.

?
Do blood estrogen levels accurately reflect brain estrogen levels?

No, estrogen levels in the circulation have little correlation with estrogen levels or activity in the brain. Brain hormone dynamics are tightly regulated by active transporters and the blood-brain barrier, sheltering the brain from peripheral fluctuations.

?
How does the APOE4 gene affect Alzheimer's risk differently in women compared to men?

Women who are heterozygous for APOE4 have a fourfold increased dementia risk, while those with two copies have a 12 to 15 times higher risk relative to non-carriers, which is approximately twice the risk seen in men.

?
What is the current understanding of menopausal hormone therapy (MHT) and Alzheimer's risk?

Observational research suggests that MHT initiated within 10 years of the final menstrual period may reduce Alzheimer's risk, especially for women with a hysterectomy using estrogen-only therapy. However, starting MHT more than 10 years post-menopause shows no clear benefit or may increase risk, particularly with combined estrogen-progestogen therapy.

?
Does estrogen cause cancer?

The term 'cause' is misleading; there is no evidence that estrogen itself causes cancer. While some studies, like the WHI, showed an increased incidence (not mortality) of breast cancer with specific older formulations of combined MHT, this is not seen with modern bioidentical transdermal estradiol and micronized progesterone.

?
What lifestyle factors are most important for women to support brain health?

Maximizing known lifestyle levers like consistent diet, exercise (moderate intensity, frequently enough), stress reduction, sleep hygiene, and managing cardiovascular risk factors (hypertension, insulin resistance, obesity) are crucial for building cognitive resilience and delaying the onset of Alzheimer's.

1. Implement Comprehensive Lifestyle

Proactively manage Alzheimer’s risk through a comprehensive lifestyle approach that includes diet, exercise, stress reduction, nutrition, sleep hygiene, and managing medical conditions like high blood pressure, insulin resistance, diabetes, and obesity.

2. Address Alzheimer’s Risk Early

Focus on interventions when relatively young, as the potential for delaying or preventing the accumulation of Alzheimer’s lesions in the brain is greatest before symptoms appear, as Alzheimer’s is a disease of midlife with symptoms that start in old age.

3. Prioritize Consistency in Habits

Embrace and consistently stick to brain-healthy lifestyle patterns for a long enough time, as frequent and sustained engagement is necessary to create lasting positive impacts on brain cells and resilience.

4. Women: Recognize Midlife Alzheimer’s Risk

Women should be particularly aware that Alzheimer’s disease often begins in midlife with negative brain changes, leading to symptoms much later, and women tend to show more early red flags than men.

5. Consider MHT Early for Symptoms

Consider initiating menopausal hormone therapy (MHT) as soon as symptoms appear during perimenopause, rather than waiting until full menopause, to accrue immediate benefits for vasomotor symptoms, bone health, cognitive performance, and sexual health.

6. Use MHT for Early Menopause

If experiencing premature or surgically induced menopause (e.g., oophorectomy) at a young age, hormone replacement therapy is considered the standard of care and should be used to mitigate health risks.

7. Choose Specific MHT Formulations

If considering menopausal hormone therapy, opt for transdermal estradiol with or without micronized progesterone, as this is considered the standard of care today due to a better safety profile compared to older formulations.

8. Avoid MPA in MHT

When considering menopausal hormone therapy, avoid formulations containing MPA (medroxyprogesterone acetate), as it has been linked to increased risks of breast cancer incidence and vascular damage.

9. Seek Personalized MHT Approach

When considering menopausal hormone therapy, seek a clinician who understands how to titrate doses based on individual symptoms and needs, rather than a one-size-fits-all approach.

10. Understand APOE4 Sex-Specific Risk

Women should be aware that carrying one APOE4 allele increases their dementia risk fourfold, and two APOE4 alleles increases it 12-15 times, which is approximately double the risk for men with the same genetic profile.

11. Treat Hormonal History as Vital Sign

View your hormonal history, including puberty, pregnancy, and menopause, as a vital sign that can indicate potential future cognitive decline or resilience, and discuss it with healthcare providers.

12. Address Mood Changes Proactively

Proactively address anxiety, depression, and mood changes experienced during puberty, pregnancy, or menopause, as midlife depression is a significant risk factor for Alzheimer’s, especially for women.

13. Monitor Blood Pressure Post-Preeclampsia

If you experienced pre-eclampsia during pregnancy, be vigilant about monitoring your blood pressure, as it can be a stress test indicating a higher risk for chronic hypertension and Alzheimer’s, especially during menopause.

14. Engage in Moderate Intensity Exercise

Perform moderate intensity exercise frequently enough to achieve significant health gains, as this is conducive to brain health.

15. Adjust Exercise Intensity

Prioritize higher intensity exercise if you have less time available, and distribute your efforts across lower intensities if you have more time, to optimize exercise benefits.

16. Move Regularly for Brain Health

Engage in regular physical movement to stimulate the production of BDNF and irisin in the brain, which support the health and growth of neurons and synaptic connections.

17. Reduce Inflammation & Oxidative Stress

Actively work to reduce inflammation and oxidative stress in your body, as these actions will contribute to better brain health and slower brain aging.

18. Support Brain Energy Metabolism

Aim to support healthy ATP production and reduce metabolic stress in the brain, as energetic damage can signify neurons are under stress.

19. Ensure Adequate Brain Blood Flow

Support healthy blood flow to the brain, as insufficient blood flow can be a concern for brain health.

20. Maintain Brain Volume & Hippocampus

Aim to maintain brain volume, especially in the hippocampus, as reductions in its size and density are considered a risk factor for Alzheimer’s disease.

21. Monitor White Matter Integrity

Be aware of signs of white matter integrity damage (gliosis) which can indicate inflammation or vascular insults, and monitor these as they can emerge with aging.

22. Monitor Subtle Cognitive Changes

Pay attention to subjective feelings that something is changing in your cognitive performance, even if objective tests don’t yet show impairment, as Alzheimer’s can have a preclinical phase lasting decades.

23. Explore GLP-1s for Brain Health

Stay informed about emerging research on GLP-1 agonists, as early data suggests they may reduce neuroinflammation and protein aggregation in the brain, potentially offering protection independent of weight loss or insulin sensitivity.

24. Consider MHT Post-Menopause

Women who are years past menopause may still be candidates for menopausal hormone therapy (MHT), as their brain’s estrogen receptor density may remain high, suggesting a continued appetite for estrogen.

25. Brain Estrogen Levels Are Unique

Recognize that estrogen levels in the brain are highly regulated and may not correlate directly with estrogen levels measured in the blood, which impacts understanding neurological symptoms of menopause.

26. Advocate for Breast Cancer Biomarkers

Advocate for the development of blood biomarkers for breast tissue, similar to PSA for prostate cancer, to allow for better tracking and management of breast health.

27. Advocate for MHT Research

Encourage and support more research into menopausal hormone therapy, particularly studies that provide data to guide diagnostic and treatment processes.

28. Participate in MHT Research

If you are considering starting menopausal hormone therapy, consider participating in research studies like CARE to help gather more data on its effects on Alzheimer’s biomarkers.

After aging, after getting older itself, being a woman is the strongest risk factor for developing Alzheimer's.

Lisa Mosconi

Alzheimer's is not a disease of old age. It's a disease of midlife with symptoms that start in old age.

Lisa Mosconi

I think it's so important to clarify that estrogen levels in the circulation have nothing to do or very little to do with estrogen levels in the brain.

Lisa Mosconi

Hormonal history should be considered a vital sign.

Lisa Mosconi

The brain is built for stability, whereas the rest of the body is built for change.

Lisa Mosconi

The good news is it takes a while to cause damage. The bad news is it takes a while to create resilience.

Peter Attia
2x higher
Alzheimer's disease prevalence in women Compared to men, not fully explained by longer lifespan.
~70%
Alzheimer's disease as percentage of all dementia cases Most common form of dementia.
At least a decade
Preclinical Alzheimer's disease duration Phase where pathology is present but objective symptoms are not.
~2 years
Longevity gap between men and women Example from England, not wide enough to explain 2x AD risk.
4-fold
Women's APOE4 heterozygous dementia risk increase Compared to non-carriers.
12 to 15 times higher
Women's APOE4 homozygous dementia risk increase Compared to non-carriers, approximately twice the risk of men.
32% reduced risk
MHT risk reduction for Alzheimer's/dementia (hysterectomy, estrogen-only, within 10 years of FMP) Based on observational research, consistent across most studies.
23% reduced risk
MHT risk reduction for Alzheimer's/dementia (with uterus, within 10 years of FMP) Based on observational research, trend level, some studies show increase.
$50 million
CARE Initiative funding Unrestricted program of research sponsored by Wellcome Leap.
3 years
CARE Initiative research duration High risk, high reward sprint.
Half by 2050
CARE Initiative target for reducing women's Alzheimer's risk Global effort.
330 million
Estimated women globally impacted by CARE Initiative If targets are met.
55 million
Estimated new Alzheimer's patients prevented by CARE Initiative Among women in the next 25 years, if targets are met.
14 factors
Modifiable risk factors for Alzheimer's (Lancet Commission) Account for approximately 45% of all Alzheimer's cases, sex-aggregated.
90 minutes
Estrogen receptor imaging scan time Total time for PET scan with F18-fluoroestradiol.
30 to 35 minutes
Estrogen receptor imaging tracer uptake peak Time within scan when most signal is obtained.
Less than 1 millisievert
Radiation dose for estrogen receptor imaging From 6 millicuries of F18-fluoroestradiol.